Nurse and Patient Perceptions and Preferences for Subcutaneous Autoinjectors for Inflammatory Joint or Bowel Disease: Findings from a European Survey

INTRODUCTION: Imraldi™ is a biosimilar of the anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab and was recently approved in Europe for the treatment of various inflammatory conditions. Imraldi is administered via an autoinjector device that features distinct design attributes compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenwick, Steve, Thakur, Kunal, Munro, Duncan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514039/
https://www.ncbi.nlm.nih.gov/pubmed/30790242
http://dx.doi.org/10.1007/s40744-019-0144-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514039/
https://www.ncbi.nlm.nih.gov/pubmed/30790242
http://dx.doi.org/10.1007/s40744-019-0144-8

Ejemplares similares